BACKGROUND Ankylosing spondylitis (AS) involves inflammation at the sacroiliac joint and spine attachment site. This study aimed to observe the ratio and function of peripheral regulatory Vδ1 T cells in AS patients to investigate their roles in AS pathogenesis. MATERIAL AND METHODS Peripheral blood mononuclear cells (PBMC) were separated by density-gradient centrifugation from AS patients and healthy controls. Flow cytometry was used to determine the ratio between Vδ1 and CD4 T cells of PBMC in AS patients and controls. Flow cytometry sorting (FCS) was used to obtain Vδ1 and naïve CD4 T cells with purity higher than 90%. CFSE staining method was used to detect the effect of Vδ1 T cells on proliferation of naïve CD4 T cells. The effect of Vδ1 T cells on secretion of IFN-γ from naïve CD4 T cells and the ability to secrete IL-10 from Vδ1 T cells were determined by flow cytometry. RESULTS AS patients had significantly lower Vδ1 T cell ratio in PBMC compared to controls (p<0.05), but their CD4 T cell ratio was significantly elevated (p<0.05). Functional assay showed suppression of naïve CD4 T cell proliferation and IFN-γ secretion by peripheral Vδ1 T cells in AS patients (p<0.01). AS patients also had lower IL-10 secreting level from peripheral derived Vδ1 T cells (p<0.01). CONCLUSIONS The immune suppression of peripheral Vδ1 T cell in AS patient increases the ratio of peripheral CD4 T cells and IFN-γ level, leading to AS pathogenesis. This immune suppression is mainly due to suppressed IL-10 secretion.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022634 | PMC |
http://dx.doi.org/10.12659/msm.897126 | DOI Listing |
Anticancer Res
June 2004
Zentrum für diagnostische Medizin Robert Bosch Krankenhaus, Auerbachstr. 110, D-70376 Stuttgart, Germany.
Background: One of the most often used complementary or alternative anticancer therapeutics for breast cancer is mistletoe extract with Viscum album lectin (VAA-1) as the leading component. The aim of this study was to determine the correlation between VAA-1 binding in breast cancer and disease outcome.
Materials And Methods: VAA-1 binding to either tumour cells or tumour infiltrating inflammatory cells was examined by immunohistochemical staining of paraffin tissue sections from breast cancer patients (n=226).
Anticancer Res
December 2001
Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany.
Background: Viscum album agglutinin-1 (VAA-1) is assumed to be the biologically most active ingredient of misteltoe extracts that are often used as adjuvant cancer therapy. To develop new approaches for lung cancer treatment, we evaluated the antineoplastic activity of VAA-1 alone and in combination with other chemotherapeutic drugs, including doxorubicin, cisplatin and taxol in the human lung carcinoma cell line A549.
Materials And Methods: Cytotoxicity was determined by 5-bromo-2'-deoxyuridine (BrdU) ELISA-assays and drug interaction assessed by the isobologram method.
Phytomedicine
January 1996
Institute of Medicinal Microbiology and Hygiene, University of Cologne, D-50935 Cologne, Goldenfelsstr. 19-21.
The galactoside-specific lectin (mistletoe lectin-1, VAA-1) and the N-acetylgalactosamine-specific lectin (mistletoe lectin-2, VAA-2) were purified from aqueous mistletoe extract and checked for their immunoactive potency. Regular subcutaneous administration of the optimal immunomodulating VAA-1 /VAA-2 dosage (1 ng lectin/kg body weight) could be shown to modulate thymocyte proliferation, maturation, emigration and activation in BALB/c-mice. Thus, the increase in thymocyte counts was statistically significant after VAA-1 treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!